| HER3 signaling and targeted therapy in cancer R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Oncology reviews 12 (1), 2018 | 195 | 2018 |
| PI3K inhibitors in cancer: clinical implications and adverse effects R Mishra, H Patel, S Alanazi, MK Kilroy, JT Garrett International journal of molecular sciences 22 (7), 3464, 2021 | 160 | 2021 |
| Current advances in the treatment of BRAF-mutant melanoma H Patel, N Yacoub, R Mishra, A White, L Yuan, S Alanazi, JT Garrett Cancers 12 (2), 482, 2020 | 149 | 2020 |
| BRAF mutant melanoma adjusts to BRAF/MEK inhibitors via dependence on increased antioxidant SOD2 and increased reactive oxygen species levels L Yuan, R Mishra, H Patel, S Alanazi, X Wei, Z Ma, JT Garrett Cancers 12 (6), 1661, 2020 | 28 | 2020 |
| Utilization of reactive oxygen species targeted therapy to prolong the efficacy of BRAF inhibitors in melanoma L Yuan, R Mishra, H Patel, S Abdulsalam, KD Greis, AL Kadekaro, ... Journal of Cancer 9 (24), 4665, 2018 | 25 | 2018 |
| IGF1R/IR mediates resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma H Patel, R Mishra, N Yacoub, S Alanazi, MK Kilroy, JT Garrett Cancers 13 (22), 5863, 2021 | 20 | 2021 |
| Phosphoinositide 3-Kinase (PI3K) reactive oxygen species (ROS)-activated prodrug in combination with anthracycline impairs pi3k signaling, increases DNA damage response and … R Mishra, L Yuan, H Patel, AS Karve, H Zhu, A White, S Alanazi, P Desai, ... International Journal of Molecular Sciences 22 (4), 2088, 2021 | 13 | 2021 |
| Role of reactive oxygen species and targeted therapy in metastatic melanoma R Mishra, H Patel, L Yuan, J Garrett Cancer Research Frontiers 4 (1), 101-130, 2018 | 7 | 2018 |
| HER3 alterations in cancer and potential clinical implications MK Kilroy, SY Park, W Feroz, H Patel, R Mishra, S Alanazi, JT Garrett Cancers 14 (24), 6174, 2022 | 6 | 2022 |
| Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer A Marin, AA Mamun, H Patel, H Akamatsu, D Ye, DR Sudhan, L Eli, ... Cancer Research, 2023 | 5 | 2023 |
| HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018; 12 (1): 355 R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Epub 2018/07/31. https://doi. org/10.4081/oncol. 2018.355 PMID: 30057690, 0 | 5 | |
| RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells H Patel, R Mishra, A Wier, N Mokhtarpour, EJ Merino, JT Garrett Anti-Cancer Drugs 34 (4), 519-531, 2023 | 2 | 2023 |
| Resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma H Patel, R Mishra, G Joan Cancer Research 79 (13_Supplement), 1284-1284, 2019 | 2 | 2019 |
| Role of HER3 signaling pathways in ER+ and HER2+ breast cancers R Mishra, S Alanazi, H Patel, L Yuan, JT Garrett Cancer Research 79 (13_Supplement), 389-389, 2019 | 2 | 2019 |
| HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers SM Alanazi, W Feroz, R Mishra, MK Kilroy, H Patel, L Yuan, SJ Storr, ... Plos one 18 (5), e0285251, 2023 | 1 | 2023 |
| IGF1R/IR mediates resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma. Cancers. 2021; 13: 5863 H Patel, R Mishra, N Yacoub, S Alanazi, MK Kilroy, JT Garrett s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer R Mishra, MK Kilroy, W Feroz, H Patel, JT Garrett Molecular Carcinogenesis, 2024 | | 2024 |
| role of her3 v104l mutation on tumor growth and her3 stabilization R Mishra, MK Kilroy, W Feroz, H Patel, S Alanazi, JT Garrett Cancer Research 83 (7_Supplement), 3916-3916, 2023 | | 2023 |
| RIDR-PI-103, ROS-activated PI3K inhibitor prodrug inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor resistant BRAF-mutant melanoma cells H Patel, R Mishra, A Wier, N Mokhtarpour, EJ Merino, JT Garrett Cancer Research 82 (12_Supplement), 5356-5356, 2022 | | 2022 |
| Role of her3 mutations on breast cancer oncogenesis R Mishra, MK Kilroy, H Patel, S Alanazi, JT Garrett Cancer Research 82 (12_Supplement), 5412-5412, 2022 | | 2022 |
